Pricing Log in Create free account

Coherus Oncology, Inc. (CHRS) vs Jyong Biotech Ltd. (MENS)

Coherus Oncology, Inc. and Jyong Biotech Ltd. are both Biotechnology companies. Jyong Biotech Ltd. is the larger, with a market value of $133.6M against $119.0M — 1.1× the size. Across the 4 metrics below, Coherus Oncology, Inc. leads on 2 and Jyong Biotech Ltd. on 2.

Valuation

Metric CHRS MENS Biotechnology median
P/E n/m — 10.60
P/S 2.34 — 9.40
P/B 1.96 n/m 2.13
Price to free cash flow n/m — 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 4.44 n/m 9.02
Earnings yield (133.77%) — (32.88%)
Free cash flow yield (156.84%) — (23.13%)

Profitability

Metric CHRS MENS Biotechnology median
Gross margin 68.94% — 68.51%
Operating margin (311.56%) — 0.00%
Net margin (259.41%) — 0.00%
Free cash flow margin (365.22%) — 0.00%
Return on equity (146.27%) — (51.96%)
Return on assets (41.90%) — (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CHRS MENS Biotechnology median
Revenue growth (TTM) 61.00% — 6.76%
EPS growth (last fiscal year) 472.00% (42.18%) 29.88%
Revenue growth, 5-year CAGR (38.41%) — 9.75%
Net income growth, 5-year CAGR 4.91% — 0.00%

Health

Metric CHRS MENS Biotechnology median
Debt to equity 0.61 (0.74) 0.00
Current ratio 1.77 0.45 4.97
Net debt to EBITDA 0.76 (6.89) 1.01

Dividend

Metric CHRS MENS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CHRS MENS Biotechnology median
Market cap 118.97m 133.62m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack